Abstract
Bevacizumab-vikg, an investigational ophthalmic formulation of bevacizumab, is on the threshold of being approved for on-label use in wet age-related macular degeneration. A phase III clinical trial found that this drug showed superior efficacy and comparable safety to ranibizumab. If approved by the US Food and Drug Administration and priced right, it will likely replace the current off-label compounded bevacizumab. In that case, bevacizumab-vikg would help eliminate the risks of contamination, reduced potency and availability often associated with the use of compounded medicines. It will be interesting to witness the impact this drug will have on how clinicians treat wet age-related macular degeneration.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
